The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Pranet Khetan, a Class 11 student at Shiv Nadar School, used AI and machine learning to develop the prototype and database ...

Across four prospective U.S. cohorts, 4.5% of those 18-49 years old met criteria for COPD, defined as spirometric airflow ...

ASP Isotopes (ASPI) announced that the Company’s proposed offer to acquire all of the issued ordinary shares of JSE-listed Renergen Limited has ...

Major indices were mostly higher early on Friday, with both the S&P 500 and Nasdaq Composite building on last night's record ...

There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...

Regeneron presents an interesting investment case. Its valuation doesn't fully capture Dupixent's strength or its pipeline potential. Bears worry about Eylea's patent cliff, but this seems priced in.

Kingsview Wealth Management recently bought a new stake in Vertex Pharmaceuticals. They snagged 545 shares, valued around ...